{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:50:09Z","timestamp":1790394609189,"version":"4.1.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:p>This case series identifies cases reported in the US Food and Drug Administration Adverse Event Reporting System of acute cholecystitis associated with use of glucagon-like peptide-1 receptor agonists that did not have gallbladder disease warnings in their labeling.<\/jats:p>","DOI":"10.1001\/jamainternmed.2022.3810","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:32:38Z","timestamp":1661772758000},"page":"1104","source":"Crossref","is-referenced-by-count":30,"title":["Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration"],"prefix":"10.1001","volume":"182","author":[{"given":"Daniel","family":"Woronow","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Niak","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Avigan","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Houstoun","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of New Drugs, Division of Diabetes, Lipid Disorders, and Obesity, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Kortepeter","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ild220029r1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials.","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"ild220029r2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits","year":"2021"},{"key":"ild220029r3","doi-asserted-by":"publisher","author":"Rehfeld","year":"2018","DOI":"10.1080\/00365521.2018.1530297"},{"issue":"1-3","key":"ild220029r4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","article-title":"Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.","volume":"179","author":"Keller","year":"2012","journal-title":"Regul Pept"},{"key":"ild220029r5","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Accessed June 24, 2022. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2795476\/jamainternal_woronow_2022_ld_220029_1664488354.51638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T11:08:13Z","timestamp":1664795293000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2795476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.3810","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}